Ion Channel Pharmacology

Neurotherapeutics

Volumn 4, Issue 2, 2007, Pages 184-198

  Conte Camerino, Diana ^a   Tricarico, Domenico ^a   Desaphy, Jean François ^a  

^a Faculty of Pharmacy   (Italy)

Author keywords

channelopathy; drug therapy; ion channel; neurotransmitter gated; pharmacogenetics; Voltage gated

Indexed keywords

2 AMINOPYRIDINE; 3 AMINOPYRIDINE; 3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; ACETAZOLAMIDE; CHLORIDE CHANNEL; DICLOFENAMIDE; FELBAMATE; FLECAINIDE; FLUOXETINE; LAMOTRIGINE; LIDOCAINE; MEXILETINE; NEUROTRANSMITTER; OMEGA CONOTOXIN MVIIA; PHENYTOIN; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KV1.2; RILUZOLE; SHAB POTASSIUM CHANNEL; SHAL POTASSIUM CHANNEL; SHAW POTASSIUM CHANNEL; TETRYLAMMONIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CHLORIDE CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; ZONIGRAM;

ABSENCE; ANDERSEN SYNDROME; ARTICLE; ATAXIA; CHANNEL GATING; CHANNELOPATHY; COGNITIVE DEFECT; CONGENITAL MYASTHENIC SYNDROME; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EATON LAMBERT SYNDROME; FOCAL EPILEPSY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPEREKPLEXIA; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NOCTURNAL SEIZURE; PAIN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPINOCEREBELLAR DEGENERATION;

ANIMALS; CHANNELOPATHIES; DRUG THERAPY; HUMANS; ION CHANNEL GATING; ION CHANNELS; MUTATION; PHARMACOGENETICS;

EID: 33947512419     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.01.013     Document Type: Article

References (69)

1. Ruetsch Y.A., Böni T., and Borgeat A. From cocaine to ropivacaine: the history of local anesthetic drugs. Curr Top Med Chem 1 (2001) 175-182
2. Gutman G.A., Chandy K.G., Grissmer S., et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57 (2005) 473-508
3. + channels: electrifying regulators of synaptic terminal excitability. Trends Neurosci 27 (2004) 210-217
4. Lehmann-Horn F., Lerche H., and Jurkat-Rott K. Skeletal muscle channelopathies: myotonias, periodic paralyses and malignant hyperthermia. In: Stålberg E. (Ed). Clinical neurophysiology of disorders of muscle and neuromuscular junction, including fatigue. Handbook of Clinical Neurophysiology 2 (2003), Elsevier Science, Boston 457-483
5. Vedeler C.A., Antoine J.C., Giometto B., et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13 (2006) 682-690
6. Coghlan M.J., Carroll W.A., and Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J Med Chem 44 (2001) 1627-1653
7. + channel blocking by aminopyridines. Biophys Chem 96 (2002) 1-14
8. Weisz C.J., Raike R.S., Soria-Jasso L.E., and Hess E.J. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J Neurosci 25 (2005) 4141-4145
9. Skeie G.O., Apostolski S., Evoli A., et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 13 (2006) 691-699
10. + channels. Vascul Pharmacol 38 (2002) 51-59
11. +-deficient rats. FASEB J 18 (2004) 760-761
12. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69 (2006) 273-294
13. Ashcroft F.M. From molecule to malady. Nature 440 (2006) 440-447
14. Peretz A., Degani N., and Nachman R. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 67 (2005) 1053-1066
15. Korsgaard M.P.G., Hartz B.P., Brown W.D., Ahring P.K., Strøbæk D., and Mirza N.R. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 314 (2005) 282-292
16. Wei A.D., Gutman G.A., Aldrich R., Chandy K.G., Grissmer S., and Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 57 (2005) 463-472
17. Ghatta S., Nimmagadda D., Xu X., and O'Rourke S.T. Large-conductance, calcium-activated potassium channels: structural and functional implications. Pharmacol Ther 110 (2006) 103-116
18. + channels. Neuromuscul Disord 16 (2006) 39-45
19. Tricarico D., Mele A., and Conte Camerino D. Phenotype-dependent functional and pharmacological properties of BK channels in skeletal muscle: effects of microgravity. Neurobiol Dis 20 (2005) 296-302
20. Szewczyk A., Skalska J., Glab M., et al. Mitochondrial potassium channels: from pharmacology to function. Biochim Biophys Acta 1757 (2006) 715-720
21. Leniger T., Wiemann M., Bingmann D., Widman G., Hufnagel A., and Bonnet U. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurones. Epilepsia 43 (2002) 469-474
22. Kubo Y., Adelman J.P., Clapham D.E., et al. International Union of Pharmacology. LIV. Nomenclature and structure-function relationships of inwardly rectifying potassium channels. Pharmacol Rev 57 (2005) 509-526
23. ATP channel openers: structure-activity relationships and therapeutic potentials. Med Res Rev 24 (2004) 213-266
24. Ligtenberg J.J., Van Haeften T.W., Van Der Kolk L.E., et al. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength. Clin Sci (Lond) 91 (1996) 583-589
25. + channel is mediated by inhibiting the mitochondrial permeability transition pore. Neurosci Lett 402 (2006) 184-189
26. ATP channel. Br J Pharmacol 139 (2003) 255-262
27. + channels determine their muscle-type-dependent biophysical and pharmacological properties. Proc Natl Acad Sci U S A 103 (2006) 1118-1123
28. Lesage F. Pharmacology of neuronal background potassium channels. Neuropharmacology 44 (2003) 1-7
29. Catteral W.A., Perez-Reyes E., Snutch T.P., and Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57 (2005) 411-425
30. Spacey S.D., Hildebrand M.E., Materek L.A., Bird T.D., and Snutch T.P. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol 56 (2004) 213-220
31. 2+ channels by carbonic anhydrase inhibitors. J Pharmacol Sci 95 (2004) 240-247
32. + channel inactivation by anemone toxin (ATX II) mimics the myotonic state in hyperkalaemic periodic paralysis. J Physiol 466 (1993) 501-520
33. + channels in a model of myotonia induced by ATX. Br J Pharmacol 128 (1999) 1165-1174
34. Clare J.J., Tate S.N., Nobbs M., and Romanos M.A. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today 5 (2000) 506-520
35. + channels as therapeutic targets for antiarrhythmic agents. Handb Exp Pharmacol 171 (2006) 99-121
36. + channel α subunit in voltage-dependent gating and drug block. J Biol Chem 277 (2002) 35393-35401
37. Hille B. Ion channels of excitable membranes. 3rd ed. (2001), Sinauer Associates, Sunderland, MA
38. Heatwole C., and Moxley III R.T. The nondystrophic myotonias. Neurotherapeutics 4 (2007) 238-251
39. Trip J., Drost G., van Engelen B.G., and Faber C.G. Drug treatment for myotonia. Cochrane Database Syst Rev 1 (2006) CD004762
40. Weckbecker K., Wurz A., Mohammadi B., et al. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord 10 (2000) 31-39
41. Desaphy J.-F., De Luca A., Tortorella P., De Vito D., George Jr. A.L., and Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57 (2001) 1849-1857
42. + channel. J Physiol 537 (2001) 701-714
43. Desaphy J.-F., De Luca A., Didonna M.P., George Jr. A.L., and Conte Camerino D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J Physiol 554 (2004) 321-334
44. Berkovic S.F. Influence of molecular genetic advances on therapy for the idiopathic epilepsies. Neurotherapeutics (2007) (in press)
45. Heron S.E., Scheffer I.E., Berkovic S.F., et al. Channelopathies in idiopathic epilepsy. Neurotherapeutics 4 (2007) 295-304
46. Lucas P.T., Meadows L.S., Nicholls J., and Ragsdale D.S. An epilepsy mutation in the β1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res 64 (2005) 77-84
47. Tate S.K., Depondt C., Sisodiya S.M., et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 102 (2005) 5507-5512
48. Legroux-Crespel E., Sassolas B., Guillet G., Kupfer I., Dupre D., and Misery L. Treatment of familial erythermalgia with the association of lidocaine and mexiletine. [In French]. Ann Dermatol Venereol 130 (2003) 429-433
49. Waxman S.G., and Dib-Hajj S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med 11 (2005) 555-562
50. + channels and central pain. Trends Neurosci 29 (2006) 207-215
51. Lai J., Porreca F., Hunter J.C., and Gold M.S. Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 44 (2004) 371-397
52. Nassar M.A., Baker M.D., Levato A., et al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain 2 (2006) 33
53. Sindrup S.H., and Jensen T.S. Are sodium channel blockers useless in peripheral neuropathic pain?. [Editorial]. Pain (2006) Oct. 17 [Epub ahead of print]
54. + channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 110 (2004) 166-174
55. Meola G., and Sansone V. Treatment in myotonia and periodic paralysis. Rev Neurol (Paris) 160 (2004) S55-S69
56. + channel blockade. J Neurosurg Anesthesiol 16 (2004) 100-101
57. Lenkey N., Karoly R., Kiss J.P., Szasz B.K., Vizi E.S., and Mike A. The mechanism of activity-dependent sodium channel inhibition by the antidepressants fluoxetine and desipramine. Mol Pharmacol 70 (2006) 2052-2063
58. Wallace C.H., Baczko I., Jones L., Fercho M., and Light P.E. Inhibition of cardiac voltage-gated sodium channels by grape polyphenols. Br J Pharmacol 149 (2006) 657-665
59. Desaphy J.F., Pierno S., De Luca A., Didonna P., and Conte Camerino D. Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders. Mol Pharmacol 63 (2003) 659-670
60. Bezzina C.R., and Tan H.L. Pharmacological rescue of mutant ion channels. Cardiovasc Res 55 (2002) 229-232
61. - channels gleaned from human genetic disease and mouse models. Annu Rev Physiol 67 (2005) 779-807
62. Pusch M., Liantonio A., De Luca A., and Conte Camerino D. Pharmacology of CLC chloride channels and transporters. In: Pusch M. (Ed). Chloride movements across cellular membranes. Advances in Molecular and Cell Biology 38 (2007), Elsevier, Amsterdam 83-107
63. Cuppoletti J., Malinowska D.H., Tewari K.P., et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 287 (2004) C1173-C1183
64. De Luca A., Pierno S., Liantonio A., Camerino C., and Conte Camerino D. Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channels. Br J Pharmacol 125 (1998) 477-482
65. Conte Camerino D., Tricarico D., Pierno S., et al. Taurine and skeletal muscle disorders. Neurochem Res 29 (2004) 135-142
66. Eguchi H., Tsujino A., Kaibara M., et al. Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve 34 (2006) 292-297
67. Desaphy J.-F., Rolland J.-F., Valente E.M., LoMonaco M., and Conte Camerino D. Functional alteration of ClC-1 channel mutants associated with transient weakness in myotonia congenita. [Abstract 1291-Pos]. Biophys J (2007) [Epub in advance of print]
68. Bowery N.G., and Smart T.G. GABA and glycine as neurotransmitters: a brief history. Br J Pharmacol 147 (2006) S109-S119
69. Cascio M. Modulating inhibitory ligand-gated ion channels. AAPS J 8 (2006) E353-E361